Alloc-Orn(Boc)-OH | 947401-26-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Alloc-Orn(Boc)-OH
• 英文别名: N^α-Alloc-N^δ-Boc-L-ornithine；(S)-2-(((Allyloxy)carbonyl)amino)-5-((tert-butoxycarbonyl)amino)pentanoic acid；(2S)-5-[(2-methylpropan-2-yl)oxycarbonylamino]-2-(prop-2-enoxycarbonylamino)pentanoic acid
• CAS: 947401-26-5
• 化学式: C₁₄H₂₄N₂O₆
• 分子量: 316.354
• InChiKey: IHXJYHSRKKRBPX-JTQLQIEISA-N

物化性质

• 沸点：
  504.9±50.0 °C(Predicted)
• 密度：
  1.153±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  22
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Alloc-Orn(Boc)-OH 在 4-二甲氨基吡啶 、 四(三苯基膦)钯 、 amberlyst-15 、 potassium tert-butylate 、 sodium cyanoborohydride 、 溶剂黄146 、 N,N'-二环己基碳二亚胺 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 64.5h， 生成
  参考文献：
  名称：

  Studies directed toward the synthesis of naturally occurring acyltetramic acids. 2. Preparation of the macrocyclic subunit of ikarugamycin

  摘要：

  DOI：

  10.1021/jo00376a101
• 作为产物：
  描述：

  L-鸟氨酸盐酸盐 在 碳酸氢钠 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 16.0h， 生成 Alloc-Orn(Boc)-OH
  参考文献：
  名称：

  Studies directed toward the synthesis of naturally occurring acyltetramic acids. 2. Preparation of the macrocyclic subunit of ikarugamycin

  摘要：

  DOI：

  10.1021/jo00376a101

文献信息

• CANCER IMAGING AND TREATMENT
  申请人：Technische Universitat Munchen

  公开号：US20140039153A1

  公开（公告）日：2014-02-06

  A compound, or a pharmaceutically acceptable salt or ester thereof, comprises the structure: [(P1-S1 j ) p -L-(S2 q -P2) r ] t wherein: P1 and P2, which may be the same or different, are cyclic oligopeptide moieties, at least one of P1 and P2 having the motif B-Arg or B-(Me)Arg within the cyclic moiety, wherein B is a basic amino acid, a derivative thereof, or phenylalanine or a derivative thereof; S1 and S2 are spacer groups, which may be the same or different; L is a linker moiety containing at least two functional groups for attachment of the cyclic oligopeptides or spacer groups; n and q are independently 0 or 1; p and r are independently integers of 1 or more; and t is an integer of 1 or more, provided that, when t, p or r is greater than 1, the cyclic oligopeptide moiety, spacer group and/or the value of j or q may be the same or different between the multiple (P1-S1 j ) moieties or multiple (S2 q -P2) moieties.

  一种化合物，或其药用可接受的盐或酯，包括结构：[(P1-S1j)p-L-(S2q-P2)r]t其中：P1和P2，可能相同或不同，是环状寡肽基团，P1和P2中至少一个具有环状基团内的B-Arg或B-(Me)Arg基序，其中B是一种碱性氨基酸，其衍生物，苯丙氨酸或其衍生物；S1和S2是间隔基团，可能相同或不同；L是一个连接基团，含有至少两个功能基团，用于连接环状寡肽基团或间隔基团；n和q独立地为0或1；p和r独立地为1或更多的整数；t是1或更多的整数，但当t、p或r大于1时，环状寡肽基团、间隔基团和/或j或q的值在多个(P1-S1j)基团或多个(S2q-P2)基团之间可能相同或不同。
• Convergent Approaches for the Synthesis of the Antitumoral Peptide, Kahalalide F. Study of Orthogonal Protecting Groups
  作者：Carolina Gracia、Albert Isidro-Llobet、Luis J. Cruz、Gerardo A. Acosta、Mercedes Álvarez、Carmen Cuevas、Ernest Giralt、Fernando Albericio

  DOI：10.1021/jo060976f

  日期：2006.9.1

  its synthetic analogues are the most promising compounds of the Kahalalide family because they show antitumoral activity. Linear solid-phase syntheses of Kahalalide F have been reported. Here we describe several new improved synthetic routes based on convergent approaches with distinct orthogonal protection schemes for the preparation of Kahaladide analogues. These strategies allow a better control

  Kahalalide化合物是从软体动物夏威夷食草海洋物种Elysia rufescens及其饮食中的绿藻Bryopsis sp中分离出来的肽。Kahalalide F及其合成类似物是Kahalalide家族中最有前途的化合物，因为它们显示出抗肿瘤活性。已经报道了Kahalalide F的线性固相合成。在这里，我们介绍了基于融合方法的几种新的改进的合成路线，这些路线具有独特的正交保护方案，用于制备Kahaladide类似物。这些策略可以更好地控制和表征中间体，因为在溶液中进行的反应更多。
• Cancer Imaging and Treatment
  申请人：Wester Hans Jürgen

  公开号：US20100240072A1

  公开（公告）日：2010-09-23

  A compound, or a pharmaceutically acceptable salt or ester thereof, comprises the structure: [(P1-S1 j ) p -L-(S2 q -P2) r ] t wherein: P1 and P2, which may be the same or different, are cyclic oligopeptide moieties, at least one of P1 and P2 having the motif B-Arg or B-(Me) Arg within the cyclic moiety, wherein B is a basic amino acid, a derivative thereof, or phenylalanine or a derivative thereof; S1 and S2 are spacer groups, which may be the same or different; L is a linker moiety containing at least two functional groups for attachment of the cyclic oligopeptides or spacer groups; n and q are independently 0 or 1; p and r are independently integers of 1 or more; and t is an integer of 1 or more, provided that, when t, p or r is greater than 1, the cyclic oligopeptide moiety, spacer group and/or the value of j or q may be the same or different between the multiple (P1-S1 j ) moieties or multiple (S2 q -P2) moieties.

  该化合物或其药学上可接受的盐或酯包括结构：[(P1-S1j)p-L-(S2q-P2)r]t，其中：P1和P2可以相同也可以不同，是环状寡肽基团，其中至少一个P1和P2在环状基团内具有B-Arg或B-(Me) Arg基序，其中B是一种碱性氨基酸，其衍生物，苯丙氨酸或其衍生物；S1和S2是间隔基团，可以相同也可以不同；L是一个连接基团，含有至少两个功能基团，用于连接环状寡肽或间隔基团；n和q独立地为0或1；p和r独立地为1或更多的整数；t是1或更多的整数，但当t，p或r大于1时，环状寡肽基团，间隔基团和/或j或q的值可能在多个（P1-S1j）基团或多个（S2q-P2）基团之间相同或不同。
• Introduction of Functional Groups into Peptides via <i>N</i>-Alkylation
  作者：O. Demmer、I. Dijkgraaf、M. Schottelius、H.-J. Wester、H. Kessler

  DOI：10.1021/ol800654n

  日期：2008.5.1

  An optimized protocol for the mild and selective Fukuyama-Mitsunobu reaction was used for mono- and di-N-alkylation on solid support. Thereby, nonfunctionalized aliphatic and aromatic residues are quickly introduced into transiently protected, primary amines of a linear peptide. N-Alkylation can also be used to implement alkyl chains carrying (protected) functionalities suited for subsequent modification. Applicability of this method is demonstrated by various N-alkylated analogues of a cyclic CXCR4 receptor antagonist originally developed by Fujii et.al.
• US8628750B2
  申请人：——

  公开号：US8628750B2

  公开（公告）日：2014-01-14